Join Growin Stock Community!

Biorestorative therapies, inc.BRTX.US Overview

US StockHealthcare
(No presentation for BRTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BRTX AI Insights

BRTX Overall Performance

BRTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BRTX Recent Performance

-4.68%

Biorestorative therapies, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BRTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BRTX Key Information

BRTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BRTX Profile

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Price of BRTX

BRTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BRTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.90
PB Ratio
2.46
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
93.34%
Net Margin
-3304.77%
Revenue Growth (YoY)
1.70%
Profit Growth (YoY)
1.59%
3-Year Revenue Growth
-25.90%
3-Year Profit Growth
-65.13%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.43
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.90
PB Ratio
2.46
Price-to-FCF
-
Gross Margin
93.34%
Net Margin
-3304.77%
Revenue Growth (YoY)
1.70%
Profit Growth (YoY)
1.59%
3-Year Revenue Growth
-25.90%
3-Year Profit Growth
-65.13%

  • When is BRTX's latest earnings report released?

    The most recent financial report for Biorestorative therapies, inc. (BRTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BRTX's short-term business performance and financial health. For the latest updates on BRTX's earnings releases, visit this page regularly.

  • What is the operating profit of BRTX?

    According to the latest financial report, Biorestorative therapies, inc. (BRTX) reported an Operating Profit of -3.71M with an Operating Margin of -31,432.3% this period, representing a decline of 62.18% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BRTX's revenue growth?

    In the latest financial report, Biorestorative therapies, inc. (BRTX) announced revenue of 11.8K, with a Year-Over-Year growth rate of -94.95%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does BRTX have?

    At the end of the period, Biorestorative therapies, inc. (BRTX) held Total Cash and Cash Equivalents of 602.44K, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BRTX go with three margins increasing?

    In the latest report, Biorestorative therapies, inc. (BRTX) did not achieve the “three margins increasing” benchmark, with a gross margin of 10.4%%, operating margin of -31,432.3%%, and net margin of -25,748.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BRTX's profit trajectory and future growth potential.

  • Is BRTX's EPS continuing to grow?

    According to the past four quarterly reports, Biorestorative therapies, inc. (BRTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BRTX?

    Biorestorative therapies, inc. (BRTX)'s Free Cash Flow (FCF) for the period is -2.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 65.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.